miRagen Therapeutics Inc Receives a Buy from Cowen & Co.

By Austin Angelo

In a report released today, Ritu Baral from Cowen & Co. reiterated a Buy rating on miRagen Therapeutics Inc (NASDAQ: MGEN). The company’s shares opened today at $9.54.

According to TipRanks.com, Baral is a 5-star analyst with an average return of 10.1% and a 43.6% success rate. Baral covers the Healthcare sector, focusing on stocks such as Synergy Pharmaceuticals Inc, Global Blood Therapeutics, and Protalix Biotherapeutics.

miRagen Therapeutics Inc has an analyst consensus of Moderate Buy, with a price target consensus of $19.

Based on miRagen Therapeutics Inc’s latest earnings report for the quarter ending March 31, the company posted quarterly revenue of $462K and GAAP net loss of $6.99 million. In comparison, last year the company earned revenue of $818K and had a GAAP net loss of $2.76 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Signal Genetics, Inc. is a commercial stage, molecular diagnostic company. It provides innovative diagnostic services that help physicians make better-informed decisions concerning the care of their patients suffering from cancer. The company was founded in January 2010 and is headquartered in Carlsbad, CA.